Opinion/decision on a Paediatric investigation plan (PIP): Tecartus, brexucabtagene autoleucel, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and

Opinion/decision on a Paediatric investigation plan (PIP): Tecartus, brexucabtagene autoleucel, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps);Oncology, PIP number: P/0221/2024